MX2019006527A - Moduladores de la actividad del complemento. - Google Patents
Moduladores de la actividad del complemento.Info
- Publication number
- MX2019006527A MX2019006527A MX2019006527A MX2019006527A MX2019006527A MX 2019006527 A MX2019006527 A MX 2019006527A MX 2019006527 A MX2019006527 A MX 2019006527A MX 2019006527 A MX2019006527 A MX 2019006527A MX 2019006527 A MX2019006527 A MX 2019006527A
- Authority
- MX
- Mexico
- Prior art keywords
- modulators
- complement activity
- methods
- polypeptide
- therapeutics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/30—Syringes for injection by jet action, without needle, e.g. for use with replaceable ampoules or carpules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
Abstract
La presente divulgación se refiere a moduladores de polipéptidos de la actividad del complemento, incluyendo moduladores de polipéptidos cíclicos. Se incluyen métodos de utilización de dichos moduladores como agentes terapéuticos. También se proporcionan métodos de medición de C5 y complejos relacionados utilizando agentes de unión a C5.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662430959P | 2016-12-07 | 2016-12-07 | |
US201762491702P | 2017-04-28 | 2017-04-28 | |
US201762525284P | 2017-06-27 | 2017-06-27 | |
US201762555711P | 2017-09-08 | 2017-09-08 | |
PCT/US2017/065005 WO2018106859A1 (en) | 2016-12-07 | 2017-12-07 | Modulators of complement activity |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006527A true MX2019006527A (es) | 2019-08-01 |
Family
ID=60957432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006527A MX2019006527A (es) | 2016-12-07 | 2017-12-07 | Moduladores de la actividad del complemento. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11123399B2 (es) |
EP (1) | EP3551210A1 (es) |
JP (2) | JP7301741B2 (es) |
KR (1) | KR20190093196A (es) |
CN (1) | CN110087668A (es) |
AU (1) | AU2017370692A1 (es) |
BR (1) | BR112019011053A2 (es) |
CA (1) | CA3045114A1 (es) |
IL (1) | IL266641A (es) |
MX (1) | MX2019006527A (es) |
TW (1) | TW201836634A (es) |
WO (1) | WO2018106859A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ727420A (en) | 2014-06-12 | 2018-06-29 | Ra Pharmaceuticals Inc | Modulation of complement activity |
PT3250230T (pt) | 2015-01-28 | 2021-12-07 | Ra Pharmaceuticals Inc | Moduladores da atividade do complemento |
EP3389692B1 (en) | 2015-12-16 | 2020-03-04 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
US11123399B2 (en) | 2016-12-07 | 2021-09-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
WO2019112984A1 (en) * | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
MX2021013010A (es) | 2019-04-24 | 2022-01-18 | Ra Pharmaceuticals Inc | Composiciones y metodos para modular la actividad del complemento. |
US20220257697A1 (en) | 2019-06-04 | 2022-08-18 | Ra Pharmaceuticals, Inc. | Inflammatory disease treatment with complement inhibitors |
EP4028126A1 (en) | 2019-09-12 | 2022-07-20 | RA Pharmaceuticals, Inc. | Neurological disease treatment with complement inhibitors |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4271068A (en) | 1968-05-10 | 1981-06-02 | Ciba-Geigy Corporation | Process for the manufacture of cystine-containing peptides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4033940A (en) | 1975-11-12 | 1977-07-05 | Armour Pharmaceutical Company | Cyclization of peptides |
US4216141A (en) | 1978-07-19 | 1980-08-05 | The Salk Institute For Biological Studies | Method for cyclization of peptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5371109A (en) | 1986-07-01 | 1994-12-06 | Drilletten Ab | Controlled release composition for a biologically active material dissolved or dispersed in an L2-phase |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
ES2118066T3 (es) | 1989-10-05 | 1998-09-16 | Optein Inc | Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos. |
US5585353A (en) | 1990-02-02 | 1996-12-17 | The Rockefeller University | Antibiotic peptides containing D-amino acids |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5843701A (en) | 1990-08-02 | 1998-12-01 | Nexstar Pharmaceticals, Inc. | Systematic polypeptide evolution by reverse translation |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
DK1136556T3 (da) | 1991-11-25 | 2005-10-03 | Enzon Inc | Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner |
AU684510B2 (en) | 1993-05-28 | 1997-12-18 | Chiron Corporation | Method for selection of biologically active peptide sequences |
PT710243E (pt) | 1993-06-29 | 2000-11-30 | Ferring Bv | Sintese melhorada de peptidos ciclicos. |
US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5834318A (en) | 1995-05-10 | 1998-11-10 | Bayer Corporation | Screening of combinatorial peptide libraries for selection of peptide ligand useful in affinity purification of target proteins |
US5912014A (en) | 1996-03-15 | 1999-06-15 | Unigene Laboratories, Inc. | Oral salmon calcitonin pharmaceutical products |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
WO1998016636A1 (fr) | 1996-10-17 | 1998-04-23 | Mitsubishi Chemical Corporation | Molecule permettant d'homologuer un genotype et un phenotype, et utilisation de celle-ci |
US5922680A (en) | 1996-10-23 | 1999-07-13 | Ferring, B.V. | Stabilized composition for oral administration of peptides |
RU2233878C2 (ru) | 1997-01-21 | 2004-08-10 | Дзе Дженерал Хоспитал Корпорейшн | Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
EP0896001A1 (en) | 1997-08-08 | 1999-02-10 | Daicel Chemical Industries, Ltd. | Method for preparing oxytocin antagoniste derivatives, intermediates for the preparation of oxytocin antagonist derivatives and method for preparing the intermediates |
US6429301B1 (en) | 1998-04-17 | 2002-08-06 | Whitehead Institute For Biomedical Research | Use of a ribozyme to join nucleic acids and peptides |
NZ509410A (en) | 1998-08-07 | 2003-08-29 | Emisphere Tech Inc | Compounds and compositions for delivering active agents |
WO2000021559A2 (en) | 1998-10-09 | 2000-04-20 | Musc Foundation For Research Development | Blocking factor b to treat complement-mediated immune disease |
US6962781B1 (en) | 2000-05-19 | 2005-11-08 | Proteonova, Inc. | In vitro evolution of nucleic acids and encoded polypeptide |
US7244701B2 (en) | 2000-06-16 | 2007-07-17 | Zealand Phama A/S | Diuretic peptide conjugate |
ES2387275T3 (es) | 2003-05-15 | 2012-09-19 | Genentech, Inc. | Métodos y composiciones para la prevención y el tratamiento de la sepsis |
WO2005023866A2 (en) | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
EP1706098A4 (en) | 2003-11-26 | 2012-08-15 | Supernus Pharmaceuticals Inc | MICELLAR SYSTEMS SUITABLE FOR THE DELIVERY OF LIPOPHILIC OR HYDROPHOBIC COMPOUNDS |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
GB0412530D0 (en) | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
WO2006066258A2 (en) | 2004-12-17 | 2006-06-22 | Neose Technologies, Inc. | Lipoconjugation of peptides |
US9649382B2 (en) | 2005-01-14 | 2017-05-16 | Camurus Ab | Topical bioadhesive formulations |
DE602005026998D1 (de) | 2005-01-14 | 2011-04-28 | Camurus Ab | Somatostatin-analog-formulierungen |
PT1844337E (pt) | 2005-01-24 | 2014-04-03 | Pepscan Systems Bv | Compostos ligantes, compostos imunogénicos e peptidomiméticos |
EP1874289A2 (en) | 2005-03-29 | 2008-01-09 | Cardax Pharmaceuticals, Inc. | Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof |
CN103505728A (zh) | 2005-05-26 | 2014-01-15 | 科罗拉多大学评议会法人机构 | 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制 |
DK1888031T3 (da) | 2005-06-06 | 2013-02-18 | Camurus Ab | GLP-1-analogformuleringer |
CN107929731A (zh) | 2005-11-04 | 2018-04-20 | 健泰科生物技术公司 | 利用补体途径抑制剂治疗眼部疾病 |
US20090220508A1 (en) | 2006-03-15 | 2009-09-03 | Alexion Pharmaceuticals, Inc. | Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement |
EP1876183A1 (en) | 2006-07-04 | 2008-01-09 | Technische Universität München | Minimized small peptides with high affinity for factor VIII and factor VIII-like proteins |
JP2010505946A (ja) | 2006-10-10 | 2010-02-25 | アカデミシュ ジーケンハウス ビイ デ ユニヴェアズィテート ファン アムステルダム | 神経再生改善のための補体阻害 |
US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
CN101679486A (zh) | 2007-03-22 | 2010-03-24 | 诺瓦提斯公司 | C5抗原及其用途 |
US20100015139A1 (en) | 2008-07-10 | 2010-01-21 | Rekha Bansal | METHOD OF INHIBITING COMPLEMENT ACTIVATION WITH FACTOR Ba SPECIFIC ANTIBODIES AND USE THEREOF |
BRPI0811007A2 (pt) | 2007-04-30 | 2015-01-27 | Alcon Res Ltd | Tratamento de degeneração macular relacionada à idade usando inibidores de fator de complemento d |
RU2473563C2 (ru) | 2007-06-07 | 2013-01-27 | Дженентек, Инк. | АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ |
US20110142837A1 (en) | 2007-07-20 | 2011-06-16 | Trustees Of The University Of Pennsylvania | Method Of Treating Acute Respiratory Distress Syndrome |
US20110182877A1 (en) | 2007-10-02 | 2011-07-28 | Potentia Pharmaceuticals, Inc. | Sustained delivery of compstatin analogs from gels |
WO2009067191A2 (en) | 2007-11-16 | 2009-05-28 | The General Hospital Corporation | Methods and compositions for the treatment of hepatitis c virus (hcv) infection |
WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
WO2010014830A2 (en) | 2008-07-30 | 2010-02-04 | Cosmix Therapeutics Llc | Peptide therapeutics that bind vegf and methods of use thereof |
AU2009290137A1 (en) | 2008-09-03 | 2010-03-11 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
ES2940466T3 (es) | 2008-11-10 | 2023-05-08 | Alexion Pharma Inc | Métodos y composiciones para tratar trastornos asociados al complemento |
MX344322B (es) | 2009-10-16 | 2016-12-13 | Omeros Corp | Uso de una composición que comprende un agente inhibidor de masp-2 efectivo para inhibir o prevenir la aparición de agregados en la vaculatura de un sujeto que sufre de un desorden de coagulación mediado por complemento. |
MX2012005151A (es) | 2009-11-05 | 2012-08-23 | Federico Ii University Of Naples | Tratamiento de hemoglobinuria nocturna paroxismica, anemias hemoliticas y estados de enfermedad que involucran hemolisis intravascular y extravascular. |
PL2513140T3 (pl) | 2009-12-16 | 2016-04-29 | Novo Nordisk As | Podwójnie acylowane pochodne glp-1 |
WO2011106635A1 (en) | 2010-02-25 | 2011-09-01 | The Trustees Of The University Of Pennsylvania | Treatment of sepsis using complement inhibitors |
US20110269807A1 (en) | 2010-04-30 | 2011-11-03 | Allergan, Inc. | Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase |
TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
NZ746139A (en) | 2011-04-08 | 2023-11-24 | Omeros Corp | Methods for treating conditions associated with masp-2 dependent complement activation |
WO2012162215A1 (en) | 2011-05-20 | 2012-11-29 | The Trustees Of The University Of Pennsylvania | Promotion of fracture healing using complement inhibitors |
SG194865A1 (en) | 2011-05-25 | 2013-12-30 | Camurus Ab | Controlled release peptide formulations |
WO2012174055A1 (en) | 2011-06-13 | 2012-12-20 | The Trustees Of The University Of Pennsylvania | Wound healing using complement inhibitors |
CN102321170B (zh) | 2011-09-14 | 2013-11-13 | 深圳翰宇药业股份有限公司 | 利拉鲁肽变构体及其缀合物 |
WO2013052736A2 (en) | 2011-10-06 | 2013-04-11 | The Medicines Company | Methods of treating or preventing blood loss during surgery using the serine protease inhibitor mdco-2010 |
KR102336895B1 (ko) | 2012-02-20 | 2021-12-08 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
US20130246083A1 (en) | 2012-03-16 | 2013-09-19 | Alexion Pharmaceuticals, Inc. | Methods of distributing complement-inhibiting drugs to patients receiving a complement inhibitor |
ES2755104T3 (es) | 2012-05-17 | 2020-04-21 | Ra Pharmaceuticals Inc | Inhibidores peptídicos y peptidomiméticos |
US9579360B2 (en) | 2012-06-20 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Methods of treating or preventing periodontitis and diseases associated with periodontitis |
US20130345257A1 (en) | 2012-06-26 | 2013-12-26 | The Regents Of The University Of California | Composition for lupus nephritis and methods of making and using the same |
WO2014078622A1 (en) | 2012-11-15 | 2014-05-22 | The Brigham And Women's Hospital, Inc. | Method and system for diagnosing and treating preeclampsia |
US9700633B2 (en) | 2013-01-28 | 2017-07-11 | Jenkem Technology Co., Ltd., Tianjin Branch | Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof |
US20140234275A1 (en) | 2013-02-15 | 2014-08-21 | Jason Williams | Method for treating als via the increased production of factor h |
US20150057342A1 (en) | 2013-08-21 | 2015-02-26 | Cannabics Pharmaceuticals Inc | Compositions for combined immediate and sustained release of cannabinoids, methods of manufacture and use thereof |
CN106132982A (zh) | 2014-03-20 | 2016-11-16 | 因弗拉克斯有限责任公司 | 用于治疗病毒性肺炎的C5a抑制剂 |
NZ727420A (en) * | 2014-06-12 | 2018-06-29 | Ra Pharmaceuticals Inc | Modulation of complement activity |
US20160168237A1 (en) | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
ES2704299T3 (es) | 2015-01-21 | 2019-03-15 | Pacira Pharmaceuticals Inc | Formulaciones de liposomas multivesiculares de ácido tranexámico |
PT3250230T (pt) | 2015-01-28 | 2021-12-07 | Ra Pharmaceuticals Inc | Moduladores da atividade do complemento |
WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
GB201516554D0 (en) | 2015-09-18 | 2015-11-04 | Camurus Ab | Controlled-release formulations |
EP3389692B1 (en) * | 2015-12-16 | 2020-03-04 | RA Pharmaceuticals, Inc. | Modulators of complement activity |
US11123399B2 (en) | 2016-12-07 | 2021-09-21 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
EP3682016A4 (en) | 2017-09-11 | 2021-06-02 | RA Pharmaceuticals, Inc. | FORMULATIONS FOR ADMINISTERING COMPOUNDS |
WO2019099735A1 (en) | 2017-11-15 | 2019-05-23 | Rhythm Pharmaceuticals, Inc. | Sustained release peptide formulations |
WO2019112984A1 (en) | 2017-12-04 | 2019-06-13 | Ra Pharmaceuticals, Inc. | Modulators of complement activity |
US10912734B2 (en) | 2018-05-16 | 2021-02-09 | Cipla Limited | Depot formulation |
EP3870221A1 (en) | 2018-10-22 | 2021-09-01 | RA Pharmaceuticals, Inc. | Neurological disease treatment with zilucoplan |
US20200214976A1 (en) | 2019-01-09 | 2020-07-09 | Spiral Therapeutics, Inc. | Self-gelling solutions for administration of therapeutics to the inner ear |
CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
MX2021013010A (es) | 2019-04-24 | 2022-01-18 | Ra Pharmaceuticals Inc | Composiciones y metodos para modular la actividad del complemento. |
-
2017
- 2017-12-07 US US16/466,165 patent/US11123399B2/en active Active
- 2017-12-07 EP EP17829067.2A patent/EP3551210A1/en active Pending
- 2017-12-07 TW TW106142894A patent/TW201836634A/zh unknown
- 2017-12-07 KR KR1020197016345A patent/KR20190093196A/ko not_active Application Discontinuation
- 2017-12-07 CA CA3045114A patent/CA3045114A1/en active Pending
- 2017-12-07 WO PCT/US2017/065005 patent/WO2018106859A1/en active Application Filing
- 2017-12-07 JP JP2019530399A patent/JP7301741B2/ja active Active
- 2017-12-07 AU AU2017370692A patent/AU2017370692A1/en not_active Abandoned
- 2017-12-07 BR BR112019011053A patent/BR112019011053A2/pt unknown
- 2017-12-07 CN CN201780074505.4A patent/CN110087668A/zh active Pending
- 2017-12-07 MX MX2019006527A patent/MX2019006527A/es unknown
-
2019
- 2019-05-15 IL IL266641A patent/IL266641A/en unknown
-
2021
- 2021-08-12 US US17/400,267 patent/US11723949B2/en active Active
-
2023
- 2023-06-21 JP JP2023101612A patent/JP2023116778A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW201836634A (zh) | 2018-10-16 |
AU2017370692A1 (en) | 2019-06-06 |
US11723949B2 (en) | 2023-08-15 |
KR20190093196A (ko) | 2019-08-08 |
IL266641A (en) | 2019-07-31 |
US20200038477A1 (en) | 2020-02-06 |
CA3045114A1 (en) | 2018-06-14 |
US11123399B2 (en) | 2021-09-21 |
CN110087668A (zh) | 2019-08-02 |
BR112019011053A2 (pt) | 2019-10-15 |
JP2023116778A (ja) | 2023-08-22 |
JP2020500897A (ja) | 2020-01-16 |
EP3551210A1 (en) | 2019-10-16 |
RU2019117565A3 (es) | 2021-07-19 |
JP7301741B2 (ja) | 2023-07-03 |
RU2019117565A (ru) | 2021-01-13 |
WO2018106859A1 (en) | 2018-06-14 |
US20220233632A1 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019006527A (es) | Moduladores de la actividad del complemento. | |
MX2022013454A (es) | Moduladores de la actividad del complemento. | |
PH12019500709A1 (en) | Anti-lag-3 antibodies and methods of use thereof | |
PH12020551397A1 (en) | Cot modulators and methods of use thereof | |
MX2021009309A (es) | Modulacion de la actividad del complemento. | |
PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
PH12018500714A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
EA201890337A1 (ru) | Конструкции антитела к flt3 и cd3 | |
PH12017500915A1 (en) | Cd47 antibodies, methods, and uses | |
MX2018003689A (es) | Proteinas de union a pd-1 y metodos para usarlas. | |
MY186712A (en) | Methods and compositions for inhibiting the interaction of menin with mll proteinss | |
PH12016501644A1 (en) | Binding proteins and methods of use thereof | |
WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
EA201591474A1 (ru) | Модуляторы метил-модифицирующих ферментов, композиции и их применение | |
SA519402159B1 (ar) | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها | |
MX2015003874A (es) | Modulacion de ire1. | |
PH12019502002A1 (en) | Combination theraphy | |
EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
TR201900071T4 (tr) | Kontrollü Over Stimülasyonuna Yönelik Bileşim | |
MX2022006304A (es) | Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles. | |
WO2018138032A3 (en) | NKp46 BINDING AGENTS | |
MX2017003808A (es) | Una combinacion de quinurenina y celulas presentadoras de antigeno (apc) como productos terapeuticos y metodos para uso en modulacion inmunitaria. | |
PH12014000104A1 (en) | Therapeutic methods and compositions for treating diabetes | |
ES2426017A2 (es) | Microemulsión que comprende colagenasa y usos |